Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Details Narrative)

v3.20.1
Stock-Based Compensation (Details Narrative) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2019
Apr. 02, 2019
Mar. 15, 2019
Mar. 15, 2020
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation expense           $ 1,570,652 $ 1,228,699
Proceeds from issuance of common stock           5,480,000
Research and Development Expenses [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation expense           $ 408,282 280,556
Employee Stock Purchase Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of common stock reserved   250,000          
Vesting portion of stock   ESPP share purchase dates are March 31 and September 30, with an initial six month payroll deduction period of April 1, 2019 to September 30, 2019.          
Purchase price per share percentage on ESPP plan   85.00%          
Number of common stock issued 82,722            
Proceeds from issuance of common stock $ 67,436            
Employee Stock Purchase Plan [Member] | Subsequent Event [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of common stock reserved         750,000    
Number of common stock issued         154,266    
Proceeds from issuance of common stock         $ 125,683    
2014 Long Term Incentive Equity Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of common stock reserved           7,951,081  
Shares of common stock available for grant of stock options           2,548,406  
Number of shares granted outside           500,854  
Number of stock options, granted value           $ 393,500  
Number of stock option intrinsic value             $ 0
Number of Stock Options Vested and exercisable           3,270,487 1,620,310
Number of stock options, granted           1,925,000 1,585,324
Total unrecognized stock-based compensation expense           $ 1,200,000  
Period for recognition of unrecognized compensation expense           1 year 1 month 6 days  
2014 Long Term Incentive Equity Plan [Member] | Employees [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted average fair value of stock options           $ 0.92 $ 1.21
2014 Long Term Incentive Equity Plan [Member] | Non-employees [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted average fair value of stock options           $ 1.97 1.97
2014 Long Term Incentive Equity Plan [Member] | Restricted Stock [Member] | Employment Agreement [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of restricted stock award granted     700,000        
Vesting portion of stock     Annual basis commencing March 15, 2020 and ending March 15, 2022.        
Number of restricted stock award vesting            
2014 Long Term Incentive Equity Plan [Member] | Restricted Stock [Member] | Employment Agreement [Member] | Subsequent Event [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of restricted stock award vesting       233,334      
2018 Long Term Incentive Equity Plan [Member] | Non-employees [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted average fair value of stock options           $ 0.29 $ 0.51
2018 Long Term Incentive Equity Plan [Member] | Lucid Diagnostics Inc [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of common stock reserved           2,000,000  
Shares of common stock available for grant of stock options           1,230,000  
Number of stock options, granted           300,000  
Total unrecognized stock-based compensation expense           $ 100,000  
Period for recognition of unrecognized compensation expense           1 year 9 months 18 days  
Expected dividend yield           $ 0.00  
2018 Long Term Incentive Equity Plan [Member] | Lucid Diagnostics Inc [Member] | Research and Development Expenses [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock-based compensation expense           $ 173,945 $ 53,233
2018 Long Term Incentive Equity Plan [Member] | Lucid Diagnostics Inc [Member] | Employees [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted average fair value of stock options           $ 0.32